These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34153521)

  • 1. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis.
    Serrano-Maciá M; Simón J; González-Rellan MJ; Azkargorta M; Goikoetxea-Usandizaga N; Lopitz-Otsoa F; De Urturi DS; Rodríguez-Agudo R; Lachiondo-Ortega S; Mercado-Gomez M; Gutiérrez de Juan V; Bizkarguenaga M; Fernández-Ramos D; Buque X; Baselli GA; Valenti LVC; Iruzubieta P; Crespo J; Villa E; Banales JM; Avila MA; Marin JJG; Aspichueta P; Sutherland J; Barrio R; Mayor U; Elortza F; Xirodimas DP; Nogueiras R; Delgado TC; Martínez-Chantar ML
    Mol Metab; 2021 Nov; 53():101275. PubMed ID: 34153521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
    Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
    J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease.
    Chen H; Shen F; Sherban A; Nocon A; Li Y; Wang H; Xu MJ; Rui X; Han J; Jiang B; Lee D; Li N; Keyhani-Nejad F; Fan JG; Liu F; Kamat A; Musi N; Guarente L; Pacher P; Gao B; Zang M
    Hepatology; 2018 Aug; 68(2):496-514. PubMed ID: 29457836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro.
    Wei D; Wu S; Liu J; Zhang X; Guan X; Gao L; Xu Z
    Can J Physiol Pharmacol; 2021 Aug; 99(8):775-785. PubMed ID: 33290156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver disease.
    Wu H; Zhou M; Jin Q; Wang X; Xu Y; Li M; Chen S; Tang Q; Wang Q; Hu B; Wu H; Xiao M; Qu L; Zhang Q; Liu J
    Hepatol Int; 2024 Aug; 18(4):1144-1157. PubMed ID: 38184503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway.
    Yan LS; Zhang SF; Luo G; Cheng BC; Zhang C; Wang YW; Qiu XY; Zhou XH; Wang QG; Song XL; Pan SY; Zhang Y
    Metabolism; 2022 Jun; 131():155200. PubMed ID: 35405150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
    Zhang J; Du H; Shen M; Zhao Z; Ye X
    J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
    Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
    Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of neddylation regulates dendritic cell functions via Deptor accumulation driven mTOR inactivation.
    Cheng M; Hu S; Wang Z; Pei Y; Fan R; Liu X; Wang L; Zhou J; Zheng S; Zhang T; Lin Y; Zhang M; Tao R; Zhong J
    Oncotarget; 2016 Jun; 7(24):35643-35654. PubMed ID: 27224922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MLN4924 Treatment Diminishes Excessive Lipid Storage in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD) by Stimulating Hepatic Mitochondrial Fatty Acid Oxidation and Lipid Metabolites.
    Ge M; Huang L; Ma Y; Sun S; Wu L; Xu W; Yang D
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OXPHOS-Mediated Induction of NAD+ Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease.
    Akie TE; Liu L; Nam M; Lei S; Cooper MP
    PLoS One; 2015; 10(5):e0125617. PubMed ID: 25933096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hesperetin ameliorates hepatic oxidative stress and inflammation
    Li J; Wang T; Liu P; Yang F; Wang X; Zheng W; Sun W
    Food Funct; 2021 May; 12(9):3898-3918. PubMed ID: 33977953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
    Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
    PLoS One; 2017; 12(3):e0170591. PubMed ID: 28278289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro.
    Mahli A; Seitz T; Beckröge T; Freese K; Thasler WE; Benkert M; Dietrich P; Weiskirchen R; Bosserhoff A; Hellerbrand C
    Cells; 2019 May; 8(5):. PubMed ID: 31096638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensinogen in hepatocytes contributes to Western diet-induced liver steatosis.
    Tao XR; Rong JB; Lu HS; Daugherty A; Shi P; Ke CL; Zhang ZC; Xu YC; Wang JA
    J Lipid Res; 2019 Dec; 60(12):1983-1995. PubMed ID: 31604805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exogenous galanin alleviates hepatic steatosis by promoting autophagy via the AMPK-mTOR pathway.
    Zhu S; Wang S; Luo T
    Arch Biochem Biophys; 2023 Aug; 744():109689. PubMed ID: 37429535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.